Simultaneous Measurement and Responsive Treatment (SMART01): A Feasibility Study of the SynerG TM CGM sensor Integrated with the Niia Essential Insulin Patch Pump System in Persons with Type 1 Diabetes.

Start Date24 Mar 2025

Sponsor / Collaborator-

ACTRN12625000054415

/ Not yet recruitingNot ApplicableIIT

Effect of early automated insulin delivery on HbA1c and equity in young Maori and/or Pacific Peoples with type 1 diabetes (Early AID Study)

Start Date27 Jan 2025

Sponsor / Collaborator-

IRCT20241103063580N1

/ RecruitingNot ApplicableIIT

Effect of Coughing Technique, ShotBlocker, and Vibration on Pain and Satisfaction During Subcutaneous Insulin Injections for Adults Patients with Type 2 Diabetes mellitus: A Randomized Controlled Trial

Start Date01 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with NNC0268-0965

100 Translational Medicine associated with NNC0268-0965

100 Patents (Medical) associated with NNC0268-0965

121,587

Literatures (Medical) associated with NNC0268-0965

31 Dec 2025·ANNALS OF MEDICINE

Bioengineering and omics approaches for Type 1 diabetes practical research: advancements and constraints

Review

Author: Li, Ling ; An, Zhenmei ; Peng, Yihua ; Peng, Xi ; Zhou, Guangju

Insulin dependency arises from autoimmunity that targets the β cells of the pancreas, resulting in Type 1 diabetes (T1D). Despite the fact that T1D patients require insulin for survival, insulin does not provide a cure for this disease or prevent its complications. Despite extensive genetic, molecular, and cellular research on T1D over the years, the translation of this understanding into effective clinical therapies continues to pose a significant obstacle. It is therefore difficult to develop effective clinical treatment strategies without a thorough understanding of disease pathophysiology. Pancreatic tissue bioengineering models of human T1D offer a valuable approach to examining and controlling islet function while tackling various facets of the condition. And in recent years, due to advances in high-throughput omics analysis, the genotypic and molecular profiles of T1D have become finer tuned. The present article will examine recent progress in these areas, along with their utilization and constraints in the realm of T1D.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up

Article

Author: El-Dahiyat, Faris ; Mohammed, Khuloud Jamal ; Al Jaberi, Asma Khaled ; Al Jawamis, Dina Farhan ; Shahwan, Moyad ; Jairoun, Ammar Abdulrahman ; Ping, Chong Chee ; Dawoud, Tasnim ; Ibrahim, Baharudin

Background:

Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3-5, analyzed the impact of statin and other antihyperglycemic interventions, on the CKD progression in individuals with T2DM.

Methods:

This was a single-center retrospective cohort study based on data derived from electronic medical records (EMR) of UAE populations with diabetes mellitus, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021. T2DM patients aged ≥ 18 years who had serum HbA1c level ≥ 6.5% and using one of the statin therapies were inclusion criteria. Patients with T1DM, who had undergone permanent renal replacement therapy, with under 1 year of follow-up and missing or incomplete data were excluded from the study. The collected data encompassed socio-demographics, detailed medical history, anthropometric measurements, laboratory analyses, clinical parameters, disease characteristics, and medications.

Results:

Our study included a cohort of 1,003 individuals. We observed 388 subjects developed CKD stages 3-5 across an average monitoring duration of 11.7 years. This resulted in a cumulative incidence of 38.7%, translating to an incidence rate of 38 cases per 1000 person-years. There was a statistically significant difference in the cumulative incidence of CKD stages 3 ± 5 according to statin therapy (P = 0.047). High intensity statin users are more likely to develop a CKD stage 3-5 compared to low/moderate intensity users and to no statin users respectively (44.3% vs 37.9%), (44.3% vs 30.9%). Conversely, the use of Biguanides was associated with a decreased probability of CKD progression (37.9% vs. 52.8%; P = 0.001), whereas Insulin users demonstrated a heightened risk (54.2% vs. 34.1%; P < 0.001).

Conclusion:

The findings emphasise the pivotal role of personalised treatment strategies, particularly concerning statin therapy and other medications, in populations at high risk.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Emergency medicine pharmacists’ interventions in the tertiary hospitals’ emergency departments in Malaysia

Article

Author: Teh, Lih Jiuan ; Tan, Shirlyn ; Tan, Sherene Su Ann ; Bhuvanendran Pillai, Anaanthan ; Selvaratanam, Manimegahlai ; Sia, Rosalind Guen Lin ; Guee, Xin Nee ; Koh, Hock Peng ; Koo, Yee Ping ; Wong, Wai Kit ; Chen, Mary Siew Yng ; Ab Jalal, Haliza

Background:

The emergency medicine (EM) pharmacist is an integrated part of the Emergency Department (ED) interdisciplinary team in many countries, including Malaysia. The presence of EM pharmacists in the ED has positively impacted patient outcomes. Data on EM pharmacists' interventions is scarce in the Asian region. In Malaysia, data on interventions done by EM pharmacists in the EDs was unavailable. This study aimed to assess the type of interventions done by EM pharmacists in the ED of tertiary public hospitals in Malaysia.

Methods:

This cross-sectional, multicenter study involved EM pharmacists from 14 tertiary hospitals in Malaysia. All accepted interventions done by EM pharmacists in the ED for patients admitted to the Red (critical) and Yellow (semi-critical) zones from January to June 2022 were extracted from the Clinical Pharmacy Report Form. All data were analyzed descriptively.

Results:

The EM pharmacists documented 1659 accepted interventions on 1584 patients during the study period. Inappropriate regimens (n = 1117, 67.3%) and incomplete prescriptions (n = 339, 20.4%) were the main categories of accepted interventions in ED. Inappropriate drug (n = 574, 34.6%), dose (n = 292, 17.6%), and frequency (n = 176, 10.6%) were the top three subcategory interventions documented under inappropriate regimens. Antimicrobials, antihypertensives, and proton pump inhibitors were the commonest drug intervened under the categories of inappropriate drug intervention. There were 272 (16.4%) accepted interventions on high-alert medications (HAMs). Insulin, enoxaparin, and noradrenaline were the most intervened HAMs.

Conclusion:

Inappropriate treatment regimens were the most common intervention category done by EM pharmacists in Malaysia. The significant number of interventions done by EM pharmacists demonstrated the importance of EM pharmacists as integral members of the EM team. This data can help improve the quality of clinical pharmacy services in the ED and is important for the future expansion of clinical pharmacy services in all EDs across Malaysia, neighbouring countries, and other developing countries.

700

News (Medical) associated with NNC0268-0965

18 Apr 2025

·www.prnewswire.com

New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection™ technology with both the Guardian™ 4 sensor and Simplera Sync™ sensor. Continue Reading MiniMed™ 780G system with Simplera Sync™ sensor The Simplera Sync™ is a disposable, all-in-one sensor that requires no fingersticks* with SmartGuard™ or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.** The MiniMed™ 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects† glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters.§ It's the only system featuring Meal Detection™ technology‡, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs. The system uses a "treat to target" approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes. Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose).1-3 It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections. "We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day," said Que Dallara, EVP and president of Medtronic Diabetes. "Our MiniMed™ 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync™ sensor, which we look forward to bringing to people living with diabetes in the U.S." A limited launch of the Simplera Sync™ sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor. About the Diabetes Business at Medtronic () Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow Medtronic on LinkedIn. *Fingersticks required in manual mode & to enter SmartGuard. If symptoms don't match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard. **Participants in a clinical trial reported the sensor was smaller and lighter than other sensors they have used. Data on file: CIP330, N=243, ages 2-80. †Refers to auto correct, which provides bolus assistance. Can deliver all correction doses automatically without user interaction, feature can be turned on and off. ‡Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating. § Refers to SmartGuard™ feature. Individual results may vary. Choudhary P. et al, Lancet Diabetes Endocrinol. 2022; S2213-8587(22)00245-5 Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714 Matejko B, et al. Diabetes Care 2022;45:2628–2635 SOURCE Medtronic plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Apr 2025

·www.pharmaceutical-technology.com

Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial

Baqsimi was launched as an option to provide rescue treatment for diabetes patients who take insulin. Credit: Diabetesmagazijn.nl on Unsplash. Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels by up to 1.6%. In the first of several readouts expected from a Phase III programme, Lilly said its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) demonstrated significant efficacy while maintaining a safety profile consistent with subcutaneously delivered GLP-1RA drugs. Eli Lilly’s stock jumped up by 13.8% at market open today (17 April). The company has a market cap of $659.93bn. This news comes just days after Pfizer culled its second obesity pill due to a liver injury incident in a patient . The manageable safety profile of Lilly’s drug marks an important development in the field of oral GLP-1RAs . Based on this update and other trials from the programme that are due to read out later this year, Lilly expects to submit an approval application for orforglipron as a weight management treatment to global regulatory agencies by the end of this year, with the submission for the treatment of type 2 diabetes (T2D) anticipated in 2026. If it gains market approval, GlobalData predicts sales of orforglipron to reach $11.8bn in 2030. The global GLP-1RA market is experiencing substantial growth and is projected to reach $125bn by 2033. GlobalData is the parent company of Clinical Trials Arena . Efficacy and safety proven in first study In the randomised, placebo-controlled, double-blind ACHIEVE-1 trial (NCT05971940), the efficacy and safety of three doses – 3mg, 12mg and 36mg – of orforglipron were evaluated in adults with T2D and inadequate glycemic control with diet and exercise alone. The drug reduced A1C levels by an average of 1.3% to 1.6% from a baseline of 8.0% after 40 weeks. It also scored in a key secondary endpoint, with more than 65% of participants taking the highest dose of orforglipron achieving an A1C less than or equal to 6.5%, which is below the American Diabetes Association’s (ADA) defined threshold for diabetes. Finally, there was significant weight loss achieved in the study, with patients losing an average of 16lb (7.9%) in the highest dose cohort. This weight loss had not plateaued, indicating potential further weight loss could be possible with further dosing. Meanwhile, the placebo cohort saw an average weight loss of 3.4lb. In addition to the efficacy, Lilly has also touted that orforglipron’s safety profile in ACHIEVE-1 and said it was consistent with the established GLP-1RA class, with the most commonly reported adverse events (AEs) being gastrointestinal-related and generally mild to moderate in severity. No hepatic safety signal was observed. Treatment discontinuation rates due to AEs were 6% in the low-dose group, 4% in the medium-dose cohort and 8% in the high-dose group compared to 1% with placebo. A Bank of America Securities report said that the four main parameters for assessing orforglipron were weight loss, blood sugar control, tolerability and safety, describing the data for all these as “solid”. This data readout was viewed as a closely watched event, and all eyes are now on Novo Nordisk’s oral GLP-1RA drug Rybelsus, which is approved for T2D, but not for weight management. The report said Rybelsus is a peptide with certain limitations, while orforglipron, being a small-molecule drug, could be easy to scale and produce. Eli Lilly’s CEO David Ricks said: “As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world. We look forward to additional data readouts later this year.” Lilly states that orforglipron is the first oral small molecule GLP-1RA, taken without food and water restrictions, to successfully complete a Phase III trial. If approved, the company is confident in its ability to launch orforglipron worldwide without supply constraints, something that until recently has plagued the GLP-1RA market . Data is set to be presented at ADA’s 85th Scientific Sessions in June 2025 and published in a peer-reviewed journal. Lilly already a powerhouse in the weight loss space Eli Lilly has already cemented its name in the GLP-1RA space with its subcutaneous therapy, tirzepatide, which is marketed as Mounjaro for T2D and Zepbound for obesity. GlobalData predicts a global sales forecast for tirzepatide of $26.75bn in 2030. Its main competitor in the space currently is Novo Nordisk, which is also a high flier with its GLP-1RA semaglutide, marketed as Ozempic for T2D and Wegovy for weight loss. Other companies are trying to break into the space, including Viking Therapeutics, which is set to initiate trials of VK2735, with the subcutaneous formulation set to enter a Phase III trial in Q2 2025 and the oral version in an ongoing Phase II study (NCT06828055). While Pfizer pulled its oral candidate, danuglipron, from development earlier this week, the company does have another obesity pill – PF-07976016, which is in a Phase IIa trial.

Phase 3Clinical ResultPhase 2Drug Approval

16 Apr 2025

·www.pharmaceutical-technology.com

Trump order eases Medicare price negotiation for small molecule drugs

Caption: Trump’s executive order seeks to change the way drug prices are negotiated under Medicare in a win for pharma lobbyists. Credit: Anna Moneymaker/ Getty Images US President Donald Trump has issued a broad executive order to lower prescription drug prices in the country, notably including a directive to ease price negotiation for small molecule drugs. The 15 April executive order was said by Trump to address the “administratively complex and expensive regime” of the Inflation Reduction Act (IRA), which has he said, “produced much lower savings than projected”. The order directs US Secretary for Health and Human Services (HHS) Robert F. Kennedy Jr. to provide the President with guidance on reform to the Medicare Drug Price Negotiation Program, along with numerous other measures in the next year. Amidst these directives is a call for the HHS Secretary to work with Congress specifically to modify the programme to align the treatment of small molecule drugs with that of biologics. Addressing the so-called “pill penalty”, the move has the potential to maintain a prolonged higher process for small molecule drugs. Under the IRA, Medicare may negotiate small molecule drug prices nine years after FDA approval versus 13 years after an approval for biologics. This significantly dissuades developers from investing in cheaper and more broadly indicated small molecule drugs, according to John Stanford, executive director of the pharma advocacy group Incubate. Critics therefore argue that aligning negotiation periods is needed to support innovation in small molecule development. A longer price negotiation timeline for small molecules would in turn afford pharmaceutical developers greater periods to generate profits before price limits are mandated, reflected in pressure on government to alleviate the pill penalty from industry lobbyists. The latest executive order also called for a reduction in Medicare Part D premiums in an effort to help access to affordable insulin and epinephrine for low-income patients, and streamline the Importation Program to better allow US states to import drugs from Canada. Despite sweeping staff cuts seen in recent weeks at the US Food and Drug Administration (FDA), President Trump called for drug approvals to be accelerated. The order also directs US Secretary for Labor, Lori Chavez-DeRemer, to propose regulations to boost transparency in dealings between employer health plans and pharmacy benefit managers (PBMs). PBMs have come under fire in a series of Congressional hearings investigating their alleged role in inflating drug prices as industry middlemen. The dealings in question involve fees paid by PBMs to brokers, encouraging health plans to contract their services.

100 Deals associated with NNC0268-0965

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	Germany	Novo Nordisk A/S	29 Oct 2019
Diabetes Mellitus, Type 1	Phase 1	Germany	Novo Nordisk A/S	05 Jun 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WSC2023	Not Applicable	Sleep Apnea Syndromes	-	Diabetic Patients on Insulin Therapy	ibtcfonene(ywjwraqfwd) = dqdiefekhu zbnovecyhx (wpyhmgvtng, 0.02) View more	-	23 Oct 2023
EASD2023	Not Applicable	Diabetes Mellitus, Type 1 \| Diabetic Retinopathy \| Retinal Diseases	652	automated insulin delivery systems (Multiple Daily Injections (MDI))	cvqwcnkhis(enxjypxehp) = Significantly lower rates of dyslipidemia in patients with AID were seen niactjmidp (lxliimoaqf ) View more	Positive	05 Oct 2023
				automated insulin delivery systems (Insulin Pump (IP) without AID)
STOP study (EASD2023)	Not Applicable	Diabetes Mellitus, Type 2	93	IDegLira	umxtijvbrt(abdcpduxxf) = jxuxqkiqlj dozecfhlpd (sjrcybztbg ) View more	Positive	05 Oct 2023
EASD2023	Not Applicable	Diabetes Mellitus, Type 2	514	insulin (Descending mode)	esitztuscm(sjyzcdoavo) = fulwmewzqe oxtcrgvbyr (piltytdogh, (1.0 - 6.0)) View more	Positive	05 Oct 2023
				insulin (Ascending mode)	esitztuscm(sjyzcdoavo) = mubrllmiew oxtcrgvbyr (piltytdogh, (0 - 4.0)) View more
EASD2023	Not Applicable	-	-	Open-source automated insulin delivery (osAID) system	lpqcpryohp(hehmhinvyi) = dcrcoqpvcf kbdtmargfn (nbbubhmpnx ) View more	Positive	05 Oct 2023
				insulin (Medtronic 780G with SmartGuard)	lpqcpryohp(hehmhinvyi) = gveypcgezk kbdtmargfn (nbbubhmpnx ) View more
INSENODIAB (ESPE2023)	Not Applicable	Diabetes Mellitus, Type 1	-	Insulin	qpmejpqwrh(mpivxhvivv) = hqxbqyxkqx twpmgzpizs (yhhuhxakfc, 0.5)	-	21 Sep 2023
				rINSENODIAB cohort	qpmejpqwrh(mpivxhvivv) = chgkddbxzs twpmgzpizs (yhhuhxakfc, 6.9)
ESPE2023	Not Applicable	Familial chylomicronaemia syndrome LPL deficiency	4	Insulin	ihfshqygnt(ajzjeosios) = trznghhkux gzoxutabet (hwtvwfklap )	-	21 Sep 2023
ADA2023	Not Applicable	Diabetes Mellitus, Type 2	96	Basal insulin only	gfqhndfsck(zcaxbarfta) = bvvifwxtdz omiqewvivn (faobzyxzgp ) View more	-	23 Jun 2023
				Multiple daily injections (MDI)	gfqhndfsck(zcaxbarfta) = wrkuajttbr omiqewvivn (faobzyxzgp ) View more
ADA2023	Not Applicable	Diabetes Mellitus, Type 1	-	Hybrid closed loop insulin delivery Medtronic MiniMed™ 670G/770G in auto mode	pmzbiymeid(uxlyoxishz) = aplrovercf tpmeicjsfu (hvedbzoqat ) View more	-	20 Jun 2023
				Sensor augmented insulin pump (SAP) therapy	pmzbiymeid(uxlyoxishz) = ttkuteamru tpmeicjsfu (hvedbzoqat ) View more
ADA2023	Not Applicable	-	251	Insulin (Control group)	eljjogzgvi(iixibmdoqc) = luoprhmbjd rblezeudjn (kyzefjafww ) View more	-	20 Jun 2023
				Insulin (Intervention group)	eljjogzgvi(iixibmdoqc) = vjqydvapmv rblezeudjn (kyzefjafww ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

NNC0268-0965

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation